As it can be seen in the State Register of Medicines (GRLS), the Ministry of Health of the Russian Federation has registered Covipir, a coronavirus therapy based on molnupiravir manufactured by Pharmasynthez.
The drug, which is released in the form of capsules, was registered on April 4. The expiration date of the registration certificate is January 1, 2023.
The indication for the use of the drug is COVID-19 with a mild or moderate course in adults who do not require supplemental oxygen, including those with an increased risk of progression of the disease to a severe course. This is stated in the instructions for use for the drug.
Contraindications to the use of Covipir include hypersensitivity to molnupiravir or any other component of the drug, pregnancy or planning for pregnancy, breastfeeding, and being under 18 years of age. The therapy should be administered under the supervision of a doctor who has experience in the treatment of coronavirus.
Pharmasynthez filed an application for registration of Covipir in March 2022.
